Maine is one of 44 states that reached a $100 million settlement with drug-maker Abbott Laboratories over its alleged off-label marketing of a seizure drug. Maine will receive $1.2 million.
In a statement released yesterday, Maine Attorney General William Schneider said the settlement is the largest consumer protection-based pharmaceutical settlement ever reached. Illinois-based Abbott Laboratories allegedly marketed its Depakote drug for off-label uses not approved by the U.S. Food and Drug Administration, which is illegal.
Depakote is approved for treatment of seizure disorders, mania associated with bipolar disorder and migraine prevention. In a complaint, the attorneys general for 44 states and the District of Columbia alleged Abbott engaged in unfair and deceptive practices when it marketed Depakote for treating schizophrenia, agitated dementia and autism.
Abbott has agreed to significantly change how it markets Depakote and to cease promoting off-label uses, among other terms.